Abstract
En masse phenotyping technology, using massively mosaic donor-derived cells and organoids, can offer enriched insights for cellotype–phenotype association in a cell-type-specific regulatory context. This emerging approach will help to discover biomarkers, inform genetic–epigenetic interactions and identify personalized therapeutic targets, offering hope for precision medicine against highly heterogeneous metabolic diseases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
